Sofia Iqbal, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr Ste 300, Lebanon, MO 65536 Phone: 417-533-6746 |
Ali Ahsen Syed, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hospital Dr, Lebanon, MO 65536 Phone: 417-533-6100 |
Dr. Neil R. Schwartzman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 441 W Elm St Ste A, Lebanon, MO 65536 Phone: 417-532-2805 Fax: 417-532-2965 |
Dr. Jeffrey Fears, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 441 W Elm St, Lebanon, MO 65536 Phone: 417-532-2805 Fax: 417-532-2848 |
Dr. Nidal Boutros, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr, Suite 300, Lebanon, MO 65536 Phone: 417-533-6746 Fax: 417-533-6740 |
Hassan Ali, M.D., Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr Ste 300, Lebanon, MO 65536 Phone: 417-533-6746 |
Dr. Ossama Al-assafeen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 120 Hospital Dr, Suite 300, Lebanon, MO 65536 Phone: 417-533-6746 Fax: 417-533-6740 |
News Archive
In most cases of prostate cancer, tumor cell growth is stimulated by the action of male hormones, or androgens, such as testosterone and dihydrotestosterone.
What makes us happy? Family? Money? Love? How about a peptide? The neurochemical changes underlying human emotions and social behavior are largely unknown. Now though, for the first time in humans, scientists at UCLA have measured the release of a specific peptide, a neurotransmitter called hypocretin, that greatly increased when subjects were happy but decreased when they were sad.
Only 2.7 percent of the U.S. adult population achieves all four of some basic behavioral characteristics that researchers say would constitute a "healthy lifestyle" and help protect against cardiovascular disease, a recent study concluded.
A combination of two devices could save the lives of several thousand cardiac arrest patients each year if implemented nationwide, suggests results of a clinical trial presented at today's American Heart Association Resuscitation Science Symposium.
Halozyme Therapeutics, Inc. today announced the commencement of a Phase 1 clinical study that will assess the effects of three approved prandial (mealtime) insulin analogs administered with its proprietary rHuPH20 (PH20) hyaluronidase enzyme compared to each of the analogs alone. This randomized, three-way cross-over design, euglycemic clamp study will compare the postprandial pharmacokinetics (PK) and glucodynamics (GD) of the insulin analogs.
› Verified 5 days ago